Kaffeetrinken kann die Leber schützen - Drei bis vier Tassen Kaffee am Tag senken Risiko für Fettleber, Zirrhose und Co
scinexx.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scinexx.de Daily Mail and Mail on Sunday newspapers.
email article
The vast majority of dialysis patients infected with COVID-19 maintained antibodies for at least 6 months, a new study found.
In a prospective analysis of over 2,000 adults on dialysis, 93% of seroprevalent patients reached an assay detectable response a SARS-CoV-2 receptor-binding domain (RBD) IgG index value of 1 or higher and maintained this level throughout a 6-month follow-up, reported Shuchi Anand, MD, of Stanford University in California, and colleagues.
On top of that, 60% of patients had IgG index values of 10 or greater classified as high the group wrote in
Annals of Internal Medicine. Of these patients, 76% maintained this antibody level throughout the 6-month follow-up.
updated: Apr 30 2021, 03:46 ist
While we all should aim to save water, an important source of life, we must also focus on improving water supplies and hygiene. Worldwide, 2.2 billion people lack access to safely managed drinking water, and 4.2 billion people lack safe sanitation. Unsafe hygiene practices are widespread, compounding the effects on people’s health. The impact on child mortality rates is devastating with more than 2,97,000 children under five who die annually from diarrhoeal diseases due to poor sanitation, poor hygiene, or unsafe drinking water.
In India, the problem of unsafe water is a huge public health concern. Apart from causing illnesses such as diarrhoea, jaundice etc, unsafe water also contributes to Hepatitis A amd E. Both these diseases are associated with inadequate and unsafe water supplies, poor sanitation and hygiene, leading to infection and inflammation of the liver.
Date Time
Share
HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target
HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target. The research was led by Dr Ruby Hoo Lai-chong (second from left), Assistant Professor, Department of Pharmacology and Pharmacy, HKUMed and Co-investigator of State Key Laboratory of Pharmaceutical Biotechnology, HKU. Dr Wu Xiaoping (second from right), post-doctoral fellow, Department of Pharmacology and Pharmacy, HKUMed is the first author. Other research team members include: Ms Zong Jiuyu (left) and Ms Zhang Zixuan (right), postgraduate student, Department of Pharmacology and Pharmacy, HKUMed.
vimarsana © 2020. All Rights Reserved.